The VIII Siberian Medical and Pharmaceutical Forum has completed in the capital of the Krasnoyarsk Territory.
Viktor Dmitriev, the General Director of the ARPM, speaking at the Forum, spoke about the preliminary results of the performance of the «Pharma-2020» program. «For 8 months of 2017, the level of retail prices for medicines from the vital and essential medicines (VEM) list decreased by 0.9%. The prices of Russian medicines from the VEM list decreased by 1.5%, and foreign production — by 0.4%. The reduction of retail prices of VEM in the price category «up to 50 rubles» was 1.4%, in the category «from 50 rubles to 500 rubles» — 0.8%, and in the category «over 500 rubles» — 0.4%. An average increase of prices of medicines which are not included in the VEM list was 8.9%. In the price category «up to 50 rubles» — 3.7%, in the category «from 50 rubles to 500 rubles» — 9.4%, and in the category «over 500 rubles» — 9%», — the speaker said.
An interesting conclusion, based on the analysis of the given data, was made by the Head of the board of the regional public organization "Moscow Pharmaceutical Society" Rosa Yagudina. «In fact, where the government saves, the compensation comes from the patient’s pocket», — the expert emphasized.
The volume of the commercial drug market in September 2017 was 59.6 billion rubles, compare with September 2016, the current year sales increased by 7.6%. An average price of a medicine at the Russian commercial market in September 2017 was 146.4 rubles. If we compare the average price of a medicine in the first month of autumn in 2017 with September 2016, then we should note that the price has decreased by 0.7%.
As a result of the "Pharma-2020" program performance, as well as the policy of import substitution, Russian medicines have been able to significantly secure the market. As a result, in September 2017, there was an increase in the share of the Russian medicines: the market share of Russian medicines was 29% in September 2017, compared to 28% last year. In physical terms there was a growth of the share by 2%, which resulted 59% in the last month of the summer of 2017. This is without taking into account the products produced by local producers.
In total worth of sales in September 2017, two pharmaceutical companies — members of the Association of the Russian Pharmaceutical Manufacturers were included in Top-3: on the second place is the pharmaceutical company Novartis, on third place — Sanofi.